Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating insulin release and decreasing glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/gastrointestinal route rather than the kidneys.
## Primary Indications
* Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for patients under 18 years of age. Use is not recommended in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary regardless of stage of chronic kidney disease or requirement for dialysis.
* **Hepatic Impairment:** No dose adjustment necessary.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes mellitus or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, diarrhea, arthralgia.
* **Serious:** Hypoglycemia (when used with insulin or secretagogues), pancreatitis (post-marketing reports), bullous pemphigoid, severe joint pain, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May significantly decrease linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; a reduction in the dose of the insulin secretagogue may be required.
## Monitoring
* **HbA1c:** Baseline then every 3–6 months.
* **Renal Function:** Not required due to clearance pathway, but relevant for overall patient metabolic profile.
* **Clinical:** Monitor for signs of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **Unique Elimination:** Linagliptin is the only DPP-4 inhibitor that does not require dose modifications for renal impairment.
* **Administration:** May be taken with or without food.
* **Drug Class:** Does not promote weight gain and has a low intrinsic risk of hypoglycemia when used as monotherapy.
* **Cost/Availability:** Often prescribed as a single-pill combination with metformin (Jentadueto) or empagliflozin (Glyxambi).
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug labeling may change. Always verify current prescribing information, institutional protocols, and patient-specific factors via official drug monographs (e.g., DailyMed, Lexicomp) before prescribing or administering medication.
